Skybiotech Healt

Which are the latest news on Skybiotech Healt?

Why is Skybiotech Healthcare Limited falling/rising?

As of 05-Sep, the stock price of Skybiotech Healthcare Limited is at 124.00, unchanged from the previous price. The stock has seen significant declines over various periods, trading below moving averages and experiencing low investor participation, indicating a bearish trend.

As of 05-Sep, the stock price of Skybiotech Healthcare Limited is currently at 124.00, with no change from the previous price (0.00%). The stock has experienced a significant decline over various periods, with a 1-week drop of 4.47% and a 1-month decrease of 25.75%. Over the past year, the stock has fallen by 32.74%, while the benchmark Sensex has only decreased by 5.21% during the same timeframe. <BR><BR>Additionally, the stock is trading below its moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with a delivery volume of 8 on September 3, which represents a staggering decline of 94.94% compared to the 5-day average delivery volume. This drop in trading activity suggests a lack of confidence among investors. <BR><BR>Overall, the combination of significant price declines, poor performance relative to the benchmark, low trading volumes, and trading below moving averages indicates that Skybiotech Healthcare Limited is experiencing a downward trend in its stock price.

Who are in the management team of Skybiotech Healt?

The management team of Skybiotech Healt includes Prakashchandra Rathi (Chairman & CFO), Poonam Rathi (Managing Director), Yogesh Nandlal Chandak (Non-Executive Director), Jagdish Manohar Mantri (Independent Director), Rakesh Somani (Independent Director), and Swati Maheshwari (Company Secretary & Compliance Officer).

The management team of Skybiotech Healt includes the following individuals:<BR><BR>1. **Prakashchandra Rathi** - Chairman & CFO<BR>2. **Poonam Rathi** - Managing Director<BR>3. **Yogesh Nandlal Chandak** - Non-Executive Director<BR>4. **Jagdish Manohar Mantri** - Independent Director<BR>5. **Rakesh Somani** - Independent Director<BR>6. **Swati Maheshwari** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Skybiotech Healt do?

Skybiotech Healthcare Limited is a micro-cap company in the Garments & Apparels industry, focusing on textile production. As of June 2026, it reported net sales of 0 Cr and a net loss of 1 Cr, with a market cap of INR 24 Cr.

Overview:<BR>Skybiotech Healthcare Limited is involved in the spinning, weaving, and finishing of textiles within the Garments & Apparels industry and operates as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as Kapil Cotex Limited in 1983 and underwent a name change to Skybiotech Healthcare Limited in 2025. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026)<BR>- Most recent Net Profit: -1 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap value: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 31<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.13<BR>- Return on Equity: -13.88%<BR>- Price to Book: 3.11<BR><BR>Contact Details:<BR>- Address: UG-276 Dreams The Mall, Gate No 3 LBS Marg Bhandup (W) Mumbai Maharashtra : 400078<BR>- Tel: 91-022-21660432<BR>- Email: kapilcotexlimited@yahoo.co.in<BR>- Website: http://www.kapilcotexlimited

Who are the peers of the Skybiotech Healt?

Skybiotech Healt's peers include Marc Loire, Indo Cotspin, Anirit Ventures, Hindoo Mills, NAPS Global, Prakash Woollen, and Laxmi Cotspin. Among them, Indo Cotspin has the highest 1-year return at 23.20%, while Skybiotech Healt and Anirit Ventures both have the lowest at -39.89%.

Peers: The peers of Skybiotech Healt are Marc Loire, Indo Cotspin, Anirit Ventures, Hindoo. Mills, NAPS Global, Prakash Woollen, and Laxmi Cotspin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Marc Loire, while Average management risk is found at Prakash Woollen, and the rest have Below Average management risk, including Indo Cotspin, Hindoo. Mills, NAPS Global, Skybiotech Healt, Laxmi Cotspin. Growth is Average at Marc Loire, Below Average at Prakash Woollen, Hindoo. Mills, and Skybiotech Healt, while NAPS Global shows Good growth, and the rest have Below Average growth. Capital Structure is Good at Marc Loire and Indo Cotspin, while Average is seen at Prakash Woollen, and the rest, including Skybiotech Healt, Laxmi Cotspin, Hindoo. Mills, and Anirit Ventures, have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indo Cotspin at 23.20%, while the lowest is Anirit Ventures at -39.89%, which is the same as Skybiotech Healt's 1-year return. Additionally, NAPS Global is the only peer with a positive six-month return, while the rest have negative returns.

How big is Skybiotech Healt?

As of 31st August, Skybiotech Healthcare Limited has a market capitalization of 24.00 Cr and reported Net Sales of 5.20 Cr with a Net Profit loss of 1.66 Cr over the latest four quarters. Shareholder's Funds were 8.99 Cr and Total Assets were 19.18 Cr as of March 2025.

As of 31st August, Skybiotech Healthcare Limited has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Skybiotech reported Net Sales of 5.20 Cr. However, the company experienced a Net Profit loss of 1.66 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 8.99 Cr and Total Assets were reported at 19.18 Cr.

Should I buy, sell or hold Skybiotech Healthcare Limited?

Are Skybiotech Healthcare Limited latest results good or bad?

Skybiotech Healthcare Limited's latest results show mixed signals; while revenue increased significantly by 90.63% quarter-on-quarter, the company still reported a net loss and negative operating margins, indicating ongoing operational challenges and poor profitability. Investors should be cautious due to the negative return on equity and persistent losses.

Skybiotech Healthcare Limited's latest results present a mixed picture, leaning towards the negative. In Q4 FY26, the company reported a net loss of ₹0.30 crores, which is a 37.50% decrease in losses compared to the previous quarter. While this indicates some improvement, the operating margin remains deeply negative at -48.09%, reflecting ongoing operational challenges.<BR><BR>On a more positive note, revenue surged by 90.63% quarter-on-quarter to ₹1.83 crores, showing a significant recovery from the previous quarter's decline. Year-on-year, revenue also increased by 79.41%. However, this revenue growth has not translated into profitability, as the company continues to struggle with converting sales into operating profits.<BR><BR>The return on equity (ROE) is notably negative at -26.36%, indicating poor capital efficiency and value destruction for shareholders. Additionally, the company has faced persistent operational losses over several quarters, raising concerns about its long-term viability.<BR><BR>Overall, while there are signs of revenue recovery, the underlying operational issues and negative profitability metrics suggest that the results are more indicative of ongoing struggles rather than a solid turnaround. Investors should approach with caution, given the company's weak fundamentals and the lack of institutional interest.

When is the next results date for Skybiotech Healthcare Limited?

The next results date for Skybiotech Healthcare Limited is 30 May 2026.

The next results date for Skybiotech Healthcare Limited is scheduled for 30 May 2026.

How has been the historical performance of Kapil Cotex?

Kapil Cotex experienced significant financial challenges in the fiscal year ending March 2025, reporting net sales of 7.05 Cr but incurring substantial losses with a profit after tax of -2.37 Cr and a net cash outflow of 9.00 Cr, resulting in a closing cash equivalent of 0.00 Cr. Despite increased sales, the company faced rising costs and a decline in profitability compared to the previous year.

Answer:<BR>The historical performance of Kapil Cotex shows significant changes from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Kapil Cotex reported net sales of 7.05 Cr, a notable increase from 0.00 Cr in the previous year. However, the total operating income also remained at 7.05 Cr, with raw material costs amounting to 3.67 Cr and total expenditure excluding depreciation rising sharply to 9.31 Cr from just 0.13 Cr. This led to an operating profit (PBDIT) of -1.88 Cr, a decline from a positive 1.87 Cr in March 2024. The company faced a profit before tax of -2.43 Cr, down from 1.88 Cr, resulting in a profit after tax of -2.37 Cr compared to 1.54 Cr the previous year. The earnings per share (EPS) reflected this downturn, falling to -12.34 from 8.02. On the balance sheet, total liabilities stood at 19.18 Cr, with total assets also at 19.18 Cr, indicating a balanced position but with significant debt of 7.20 Cr. The cash flow analysis revealed a net cash outflow of 9.00 Cr, leading to a closing cash equivalent of 0.00 Cr. Overall, the financial results indicate a challenging year for Kapil Cotex, marked by increased sales but substantial losses and cash flow issues.

Who are the top shareholders of the Kapil Cotex?

The top shareholder of Kapil Cotex is Prakashchandra Rathi, holding 45.16%, with no pledged promoter holdings. The highest public shareholder is Ganesh Shivprasad Lahoti at 4.44%, while individual investors own 33.96% of the shares.

The top shareholders of Kapil Cotex include the promoters, with Prakashchandra Rathi holding the largest share at 45.16%. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings. The highest public shareholder is Ganesh Shivprasad Lahoti, who holds 4.44%. Additionally, individual investors collectively hold 33.96% of the shares.

Is Kapil Cotex overvalued or undervalued?

As of April 25, 2023, Kapil Cotex is considered a risky investment due to its negative financial ratios and poor stock performance, indicating it is overvalued compared to peers in the garments and apparel industry.

As of 25 April 2023, the valuation grade for Kapil Cotex has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued based on its financial ratios, which include a PE ratio of -11.70, an EV to EBITDA of -15.57, and a Price to Book Value of 3.08. These negative ratios suggest that the company is struggling to generate profits and is not performing well relative to its asset base.<BR><BR>In comparison with peers, Kapil Cotex's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while Embassy Office REIT is considered very expensive with a PE ratio of 23.06. The stark contrast in these ratios highlights the challenges faced by Kapil Cotex in the garments and apparel industry. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.63% compared to a positive 5.56% return for the Sensex, reinforcing the notion that Kapil Cotex is currently overvalued.

What is the technical trend for Kapil Cotex?

As of May 29, 2025, Kapil Cotex's technical trend has shifted to a moderate bearish stance, driven by bearish signals from the MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST.

As of 29 May 2025, the technical trend for Kapil Cotex has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing a bearish trend. The KST on a weekly basis is mildly bullish, but this is overshadowed by the overall bearish signals from other indicators. The Dow Theory reflects a mildly bearish stance on both weekly and monthly time frames, further supporting the bearish outlook.

Has Kapil Cotex declared dividend?

No Dividend History Available